
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Click the title above to open the Pharmaceutical Executive July 2018 issue in an interactive PDF format.
over 8 years ago
Opioid Litigation: Evading the Widening Crosshairsover 8 years ago
Patient & Customer-Centric Commercializationover 8 years ago
Compliance: The Critical Cog in Pharma Machineover 8 years ago
Gaining Ground with Stem Cells: Gil Van Bokkelen, Athersysover 8 years ago
A Seat at the Strategy Tableover 8 years ago
Regulatory Innovation Generates Breakthroughsover 8 years ago
China’s Biopharma Rise: Opportunities and Threats




